ライフサイエンスコーパス: standardized incidence ratio

1 Swedish Renal Registry was used to obtain a standardized incidence ratio.

2 out the standardized mortality ratio and the standardized incidence ratio.

3 red with that of the US population, based on standardized incidence ratio.

4 -years of follow-up; 36.5 had been expected (standardized incidence ratio = 0.85, 95% confidence inte

5 t increased in users of combination therapy (standardized incidence ratio = 0.93, 95% confidence inte

6 ed, as compared with 109.7 expected cancers (standardized incidence ratio, 0.98; 95% confidence inter

7 disease, a number similar to that expected (standardized incidence ratio = 1.2, 95% confidence inter

8 ciated with an increased risk of meningioma (standardized incidence ratio = 1.29, 95% confidence inte

9 optees without a biological parent with VTE (standardized incidence ratio) 1.51 (95% confidence inter

10 isk varied with sex and was greatest in men (standardized incidence ratio, 1.03 [95% CI, 1.02-1.03];

11 her than expected in the general population (standardized incidence ratio, 1.48; 95% confidence inter

12 bolism was seen after first dose of ChAdOx1 (standardized incidence ratio: 1.12 [95% CI: 1.05 to 1.20

13 E (n=156) were not at increased risk of VTE (standardized incidence ratio=1.07, 0.91-1.25).

14 levation was stronger than for systemic NHL (standardized incidence ratio=11.5; N = 2043).

15 eveloping TC in the general male population (standardized incidence ratio, 13.1; 95% CI, 11.5 to 15.0

16 CTGCT was diagnosed in 136 patients (standardized incidence ratio, 14.6; 95% CI, 12.2 to 17.2

17 ted for virus-related NKSCs: Kaposi sarcoma (standardized incidence ratio = 147, 95% confidence inter

18 with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidenc

19 much higher than in the general population (standardized incidence ratio, 19.1; 95% CI, 18.1 to 20.0

20 million person-years) and rhabdomyosarcoma (standardized incidence ratio, 2.62; 95% CI, 1.26 to 4.82

21 agnosed with VTE before the age of 50 years (standardized incidence ratio=2.03, 1.24-3.14).

22 o were treated with chest radiation therapy (standardized incidence ratio, 24.7 [95% CI, 19.3 to 31.0

23 sed for epilepsies without identified cause (standardized incidence ratio 3.8).

24 val = 3.13-8.11), and Merkel cell carcinoma (standardized incidence ratio = 3.15, 95% confidence inte

25 onfidence interval = 1.9-3.2), and melanoma (standardized incidence ratio = 3.3; 95% confidence inter

26 d incidence of malignancies other than NMSC (standardized incidence ratio, 3.04; 95% confidence inter

27 eased by 3-fold for NIA-LOAD/NCRAD families (standardized incidence ratio, 3.44) and 2-fold among the

28 ificantly higher incidence of ALS diagnosis (standardized incidence ratio, 3.59; 95% CI, 2.58-4.93) a

29 ed with an increased risk of hepatoblastoma (standardized incidence ratio, 3.64; 95% CI, 1.34 to 7.93

30 or epilepsy of prenatal/developmental cause (standardized incidence ratio 4.1).

31 h we denoted 'prenatal/developmental cause' (standardized incidence ratio 4.3).

32 ted in recipients with versus without tBKVN (standardized incidence ratios 4.5 vs. 1.7; N = 48 cases)

33 ort was at a 4.5-fold increased risk of CHF (standardized incidence ratio = 4.5), compared with the g

34 dence interval [CI], 1.66-5.10) and of NMSC (standardized incidence ratio, 4.59; 95% CI, 2.51-7.70).

35 l = 141-153), diffuse large B-cell lymphoma (standardized incidence ratio = 5.19, 95% confidence inte

36 osis, 291 SMNs were ascertained in 261 CCSs (standardized incidence ratio, 5.2; 95% CI, 4.6 to 5.8; e

37 ands with idiopathic generalized epilepsies (standardized incidence ratio 6.0) and epilepsies associa

38 re not treated with chest radiation therapy (standardized incidence ratios, 6.7 and 7.6, respectively

39 PCNSL compared with the general population (standardized incidence ratio = 65.1; N = 168), and this

40 east cancer was the most common solid tumor (standardized incidence ratio 75.3; 95 percent confidence

41 d risk compared with the general population (standardized incidence ratio, 9.2; 95% confidence interv

42 ot different from that of the US population (standardized incidence ratio [95% CI], 1.0 [0.6 to 1.6])

43 We calculated standardized incidence ratios, absolute excess risks, an

44 opulation-based CRE incidence, site-specific standardized incidence ratios (adjusted for age and race

45 Compared with the general population, standardized incidence ratios among patients with an ind

46 The standardized incidence ratio and the standardized mortal

47 The standardized incidence ratios and 95% confidence interva

48 ation immunosuppression were cancer-specific standardized incidence ratios and a multivariate hazard

49 in this cohort with population rates, using standardized incidence ratios and Cox proportional-hazar

50 Standardized incidence ratios and cumulative incidence f

51 We calculated standardized incidence ratios and cumulative incidence o

52 Cancer standardized incidence ratios and standardized mortality

53 We calculated the standardized incidence ratios and standardized mortality

54 Annual incidences, standardized incidence ratios, and cumulative risks of b

55 As secondary analyses, the standardized incidence ratios (based on 2 cases for each

56 Standardized incidence ratios, based on age-specific can

57 Standardized incidence ratios compared rates of AC and S

58 Relative risks (RRs) were estimated using standardized incidence ratios, comparing the observed nu

59 Standardized incidence ratios declined for subsequent ma

60 Standardized incidence ratios determined excess risk of

61 Standardized incidence ratios did not differ by type or

62 ttransplant lymphoproliferative disease have standardized incidence ratios exceeding 10- or 50-fold.

63 We calculated standardized incidence ratios, excess absolute risks, an

64 r age, race, sex, and year of diagnosis, the standardized incidence ratio for all cancers is more tha

65 The standardized incidence ratio for all malignancies (prima

66 The standardized incidence ratio for all malignant neoplasms

67 The standardized incidence ratio for any second cancer was 2

68 The estimated standardized incidence ratio for different DNMs is also

69 The standardized incidence ratio for HL with respect to age-

70 The standardized incidence ratio for patients with BD-IPMNs

71 The standardized incidence ratio for SMN was 9.5 (95% CI, 4.

72 s per 100,000 patient-years, and the overall standardized incidence ratio for suicide was 1.84 (95% c

73 The standardized incidence ratio for VTE was highest for ado

74 he antiretroviral therapy era, we calculated standardized incidence ratios for 27 NKSCs, comparing in

75 Standardized incidence ratios for all cancer were 84 in

76 Standardized incidence ratios for breast cancer were cal

77 The standardized incidence ratios for colorectal cancer were

78 These, together with standardized incidence ratios for CRC for this cohort an

79 The standardized incidence ratios for death due to neuroblas

80 The standardized incidence ratios for developing specific SM

81 imated age-specific cumulative incidence and standardized incidence ratios for epilepsy in relatives

82 ce") of neoplasms (benign and malignant) and standardized incidence ratios for malignant tumors in in

83 Standardized incidence ratios for post-transplant cardia

84 Cumulative incidence of SNs and standardized incidence ratios for second malignant neopl

85 We calculated standardized incidence ratios for siblings versus the ge

86 cumulative incidence, cumulative burden, and standardized incidence ratios for subsequent malignancie

87 Standardized incidence ratios for suicide among patient

88 The relative risk (standardized incidence ratio) for venous thromboembolism

89 Familial standardized incidence ratio (FSIR), relative risks (RRs

90 us squamous cell carcinoma, have the highest standardized incidence ratios in transplant recipients.

91 n women and 73 in men, with a large range of standardized incidence ratios observed for specific canc

92 A lung cancer standardized incidence ratio of 0.44 (95% confidence int

93 first cancer was 107.8 x 10,000 PY, giving a standardized incidence ratio of 1.1 (95% CI: 0.83-1.41).

94 A prostate cancer standardized incidence ratio of 1.14 (95% confidence int

95 among the exposed daughters, resulting in a standardized incidence ratio of 40.7 (95% CI, 13.1-126.2

96 The 3- to <12-month standardized incidence ratio of cancer was 1.5 (95% CI,

97 The standardized incidence ratio of hospitalization and deat

98 ne doses (21 days apart); by calculating the standardized incidence ratio of the observed-to-expected

99 reased compared with the general population (standardized incidence ratio of VTE, 4.2; 95% CI, 3.9 to

100 s for both invasive and in situ lip cancers (standardized incidence ratios of 15.3 and 26.2, respecti

101 We calculated risks and standardized incidence ratios of cancer for patients wit

102 Cumulative incidence and standardized incidence ratios of cancer, survival probab

103 The standardized incidence ratios of CRC were 2.2 for all IB

104 causes of death and cumulative incidence and standardized incidence ratios of key medical morbidities

105 cond cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorecta

106 Standardized incidence ratios showed excess risk for all

107 nce of SPLC among patients with IPLC and (2) standardized incidence ratio (SIR) (calculated as the SP

108 ated compared with California women overall (standardized incidence ratio (SIR) = 0.9, 95% confidence

109 or overall cancer incidence in male workers (standardized incidence ratio (SIR) = 0.91, 95% confidenc

110 elevated risks of all cancers combined (PCT: standardized incidence ratio (SIR) = 1.7, 95% confidence

111 cidence was higher for non-Hodgkin lymphoma (standardized incidence ratio (SIR) = 1.90, 95% CI: 1.01,

112 d mortality of SPCs per 10 000 person-years; standardized incidence ratio (SIR) and standardized mort

113 (absolute incidence [95% CI]) and associated standardized incidence ratio (SIR) by race and ethnicity

114 The standardized incidence ratio (SIR) for all cancers was 1

115 this study was to determine the rate of and standardized incidence ratio (SIR) for lymphoma in patie

116 The standardized incidence ratio (SIR) for MS following the

117 re diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidenc

118 ma in situ developed in 373 patients, with a standardized incidence ratio (SIR) of 5.0 (95% CI, 4.5 t

119 and End Results (SEER) population rates, the standardized incidence ratio (SIR) of SMNs was increased

120 ed 0-14 years), 5-year survival (%), and the standardized incidence ratio (SIR) of subsequent maligna

121 The calculated standardized incidence ratio (SIR) showed that mutation

122 The standardized incidence ratio (SIR) was calculated as the

123 Standardized incidence ratio (SIR) was used to estimate

124 All studies were included that reported a standardized incidence ratio (SIR), standardized mortali

125 The standardized incidence ratio (SIR), with 95% confidence

126 primary MCC, which were calculated using the standardized incidence ratio (SIR; ratio of observed to

127 Standardized incidence ratios (SIR) and 95% confidence i

128 Standardized incidence ratios (SIR) and excess absolute

129 We obtained standardized incidence ratios (SIR) and excess absolute

130 Standardized incidence ratios (SIR) were calculated to c

131 ponding background population by calculating standardized incidence ratios (SIR) with 95% CIs.

132 o the general population were assessed using standardized incidence ratios (SIR).

133 ncreased relative to the general population (standardized incidence ratio [SIR] 1.80, 95%CI 1.51-2.12

134 dividuals with adenomas >=20 mm in diameter (standardized incidence ratio [SIR] 2.07; 95% CI 1.40-2.9

135 ed significantly for acute myeloid leukemia (standardized incidence ratio [SIR] 52.3), non-Hodgkin ly

136 ndrome (MDS) or acute myeloid leukemia (AML; standardized incidence ratio [SIR] = 300; 95% CI, 210 to

137 his corresponds to a 39-fold increased risk (standardized incidence ratio [SIR] = 39; 95% CI, 26 to 5

138 A four-fold increased breast cancer risk (standardized incidence ratio [SIR] = 4.0; 95% CI, 3.0 to

139 ween BCL and TCL overall (TCL following BCL: standardized incidence ratio [SIR] = 4.7, 95% confidence

140 a-analyses evaluating incidence of anal SCC (standardized incidence ratio [SIR] vs general population

141 ancy compared with an expected number of 79 (standardized incidence ratio [SIR], 1.1; 95% CI, 0.9 to

142 he risk for ESRD in the cohort was elevated (standardized incidence ratio [SIR], 1.37; 95% confidence

143 4.3 expected from general population rates (standardized incidence ratio [SIR], 11.6, 95% confidence

144 ng SNs compared with the general population (standardized incidence ratio [SIR], 18.5, 95% CI, 15.6 t

145 ral Swedish and Danish populations combined (standardized incidence ratio [SIR], 2.0; 95% CI, 1.6-2.4

146 nosis of a new cancer after ischemic stroke (standardized incidence ratio [SIR], 2.6 [95% CI, 2.2-3.1

147 ncidence was elevated among people with HIV (standardized incidence ratio [SIR], 2.78), organ transpl

148 higher than that in the general population (standardized incidence ratio [SIR], 2.81 [95% CI, 2.10 t

149 was significantly elevated for liver cancer (standardized incidence ratio [SIR], 27.7; 95% confidence

150 h HL was 0.6%, which represents a threefold (standardized incidence ratio [SIR], 3.3; 95% confidence

151 ung field) had a high risk of breast cancer (standardized incidence ratio [SIR], 43.6; 95% CI, 27.2 t

152 ed after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL =

153 iated with higher rates of Sjogren syndrome (Standardized incidence ratio [SIR]8.14), scleroderma (SI

154 and higher incidences of de novo malignancy (standardized incidence ratio [SIR]=3.94, 95% CI, 2.09-6.

155 ed risks (P < .001) of thyroid (age-adjusted standardized incidence ratios [SIR], 32.1; 95% CI, 26.0-

156 Standardized incidence ratios (SIRs) adjusted for age, r

157 Standardized incidence ratios (SIRs) and attributable ri

158 914 to 2006, we quantified sarcoma risk with standardized incidence ratios (SIRs) and cumulative inci

159 Standardized incidence ratios (SIRs) and excess absolute

160 Standardized incidence ratios (SIRs) and standardized mo

161 Standardized incidence ratios (SIRs) and standardized mo

162 Standardized incidence ratios (SIRs) and standardized mo

163 Standardized incidence ratios (SIRs) and standardized mo

164 the background population were expressed as standardized incidence ratios (SIRs) and standardized mo

165 The standardized incidence ratios (SIRs) and the 5- and 10-y

166 Risk of skin cancer was analyzed using standardized incidence ratios (SIRs) and, for SCC, multi

167 cumulative incidence rates and age-specific standardized incidence ratios (SIRs) compared across tre

168 Standardized incidence ratios (SIRs) compared HL risk in

169 Standardized incidence ratios (SIRs) compared incidence

170 Standardized incidence ratios (SIRs) expressing risk of

171 Standardized incidence ratios (SIRs) for all SMNs combin

172 Standardized incidence ratios (SIRs) for cancer were cal

173 We calculated age- and sex-adjusted standardized incidence ratios (SIRs) for CRC in both gro

174 relatives, and calculated the registry-based standardized incidence ratios (SIRs) for different cance

175 data were used until year 2016 to calculate standardized incidence ratios (SIRs) for familial risks

176 ched controls were used for comparison using standardized incidence ratios (SIRs) for pancreatic canc

177 Standardized incidence ratios (SIRs) for senile cataract

178 Standardized incidence ratios (SIRs) for solid tumors we

179 The primary outcomes were standardized incidence ratios (SIRs) for subsequent nonk

180 Standardized incidence ratios (SIRs) measured the effect

181 The standardized incidence ratios (SIRs) of autism and ADHD

182 e estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carri

183 cs of patients and the age- and sex-adjusted standardized incidence ratios (SIRs) of cancer in famili

184 We computed absolute risks and standardized incidence ratios (SIRs) of cancer, and mort

185 The standardized incidence ratios (SIRs) of diffuse large B-

186 son regression models were used to calculate standardized incidence ratios (SIRs) of S aureus bactere

187 Standardized incidence ratios (SIRs) of SIDS were calcul

188 to identify HCC risk factors and calculated standardized incidence ratios (SIRs) to compare HCC risk

189 We used standardized incidence ratios (SIRs) to compare incidenc

190 We estimated standardized incidence ratios (SIRs) using English popul

191 Standardized incidence ratios (SIRs) were calculated as

192 Standardized incidence ratios (SIRs) were calculated by

193 Standardized incidence ratios (SIRs) were calculated by

194 Standardized incidence ratios (SIRs) were calculated for

195 Familial standardized incidence ratios (SIRs) were calculated for

196 Sex-specific age- and calendar-period standardized incidence ratios (SIRs) were calculated for

197 Standardized incidence ratios (SIRs) were calculated for

198 Standardized incidence ratios (SIRs) were calculated for

199 Standardized incidence ratios (SIRs) were calculated for

200 Standardized incidence ratios (SIRs) were calculated for

201 Standardized incidence ratios (SIRs) were calculated for

202 Standardized incidence ratios (SIRs) were calculated rel

203 Standardized incidence ratios (SIRs) were calculated to

204 Standardized incidence ratios (SIRs) were calculated to

205 Standardized incidence ratios (SIRs) were calculated to

206 Standardized incidence ratios (SIRs) were calculated usi

207 Standardized incidence ratios (SIRs) were calculated usi

208 Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) were calculated usi

209 Cumulative incidence and standardized incidence ratios (SIRs) were calculated, an

210 Sex-specific standardized incidence ratios (SIRs) were calculated.

211 Standardized incidence ratios (SIRs) were calculated.

212 Standardized incidence ratios (SIRs) were computed as es

213 Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and

214 Age- and sex-standardized incidence ratios (SIRs) were estimated by r

215 Thirty-year SMN cumulative incidence and standardized incidence ratios (SIRs) were estimated by t

216 Standardized incidence ratios (SIRs) were used for compa

217 Standardized incidence ratios (SIRs) were used to assess

218 Standardized incidence ratios (SIRs) were used to assess

219 ponding age, sex, and calendar year yielding standardized incidence ratios (SIRs) with 95% CIs.

220 ponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence

221 Standardized incidence ratios (SIRs) with 95% confidence

222 ponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence

223 Standardized incidence ratios (SIRs) with 95% confidence

224 We calculated standardized incidence ratios (SIRs) with 95% confidence

225 We estimated sex-specific standardized incidence ratios (SIRs) with corresponding

226 Standardized incidence ratios (SIRs), a proxy measure fo

227 Standardized incidence ratios (SIRs), absolute excess ri

228 We calculated standardized incidence ratios (SIRs), absolute excess ri

229 We estimated standardized incidence ratios (SIRs), absolute excess ri

230 for incident new cancers, cumulative burden, standardized incidence ratios (SIRs), and relative rates

231 Risk was calculated using standardized incidence ratios (SIRs), and risk factors w

232 SPM risk was quantified by using standardized incidence ratios (SIRs), excess absolute ri

233 Cumulative incidence of SNs, standardized incidence ratios (SIRs), excess absolute ri

234 Sex and HIV risk group-specific standardized incidence ratios (SIRs), post-AIDS relative

235 We calculated standardized incidence ratios (SIRs), relative risks (RR

236 Childhood Cancer Survivor Study to calculate standardized incidence ratios (SIRs), using Surveillance

237 al population incidence rates by calculating standardized incidence ratios (SIRs).

238 ) with those of the general population using standardized incidence ratios (SIRs).

239 Incidence rates of malignant neoplasms and standardized incidence ratios (SIRs).

240 ween living kidney donors and controls using standardized incidence ratios (SIRs).

241 pared risk with the general population using standardized incidence ratios (SIRs).

242 ents not exposed to biologics and calculated standardized incidence ratios (SIRs).

243 diagnoses and calculated absolute risks and standardized incidence ratios (SIRs).

244 mpared with risks in the general population (standardized incidence ratios [SIRs]) and the non-IVF gr

245 The standardized incidence ratio (the ratio of observed to e

246 We calculated standardized incidence ratios to compare anal cancer inc

247 eloped a risk classification system based on standardized incidence ratios, using data from the Polis

248 The standardized incidence ratio was 1.5 (95 percent confide

249 The overall cancer standardized incidence ratio was 1.5 (95% confidence int

250 ogy, and End-Results) lymphoma database, the standardized incidence ratio was 1.8 (95% CI 1.5-2.2).

251 Standardized incidence ratio was 10.9 (95% CI, 6.6 to 17

252 patients with pericarditis was 2.7%, and the standardized incidence ratio was 12.4 (95% CI, 11.2-13.7

253 The adjusted standardized incidence ratio was 224.1 (95% confidence i

254 The overall standardized incidence ratio was 3.1 (95 percent confide

255 The standardized incidence ratio was 3.5 (95% confidence int

256 cted incidence based on historical data, the standardized incidence ratio was 5.34 (95% CI, 4.48 to 6

257 A prostate cancer standardized incidence ratio was computed for the cohort

258 The CRE standardized incidence ratio was significantly higher th

259 estimated by computing an age, sex, and race standardized incidence ratio, was 2.24 (95% confidence i

260 unpaired t tests, and age- and sex-adjusted standardized incidence ratio were calculated.

261 Breast cancer standardized incidence ratios were 0.87 (95% confidence

262 n relatives of probands with focal epilepsy, standardized incidence ratios were 1.0 (95% confidence i

263 because of a history of adenomatous polyps; standardized incidence ratios were 1.6 (CI, 1.2 to 2.2)

264 The standardized incidence ratios were 1.74 (0.94 to 2.37) f

265 s with </=17, 18-21, and >/=22 risk alleles, standardized incidence ratios were 1.76, 2.08, and 2.25,

266 tives of probands with generalized epilepsy, standardized incidence ratios were 8.3 (95% confidence i

267 Standardized incidence ratios were calculated by compari

268 Standardized incidence ratios were calculated for spousa

269 Standardized incidence ratios were calculated to determi

270 incidences of second TC were estimated, and standardized incidence ratios were calculated.

271 ncidence, standardized mortality ratios, and standardized incidence ratios were compared between trea

272 Standardized incidence ratios were computed to compare C

273 0 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the pati

274 Age-adjusted standardized incidence ratios were used to assess whethe